Compare Citigroup Inc. (C) vs HCA Health Inc (HCA) Price & Performance

Citigroup (C) trades at $134.99, up 0.86% with bullish technical momentum near key resistance at $136. The stock shows strong fundamental improvement with Q2 2026 EPS beating estimates at $3.15 versus $2.72 expected, marking the second consecutive quarterly beat. Revenue reached decade highs in Q2 2026 at $91.4B with net income margin improving to 19.52%. Recent strategic hires in investment banking and digital transformation initiatives support growth prospects.

The outlook remains positive with analyst consensus target of $154.38 offering 14% upside potential. Key risks include volatile cash flow patterns with negative operating cash flow in 2025 ($-67.6B) and elevated debt levels at $287.3B long-term debt. The stock's current P/E of 14.55 appears reasonable given improving profitability and strategic repositioning underway.

HCA Healthcare trades at $413.36, up 1.09% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $449.93. The company reported strong Q2 2026 earnings of $7.59 per share, beating estimates, and has shown consistent revenue growth, reaching $75.60 billion in 2025. Recent corporate actions include dividend payments of $0.78 per share, while news highlights executive appointments and ongoing legal investigations.

The stock presents a compelling investment case with attractive valuation multiples like a P/E of 13.86 and robust profitability, but faces risks from legal probes and high debt levels. Upside potential is supported by analyst optimism and solid operational cash flow, though investors should monitor expense pressures and regulatory developments.